
We aim to evaluate the efficacy and safety of mucosal sublingual immunotherapy based on whole inactivated bacteria (MV130) in preventing wheezing attacks (WA) in children. Subjects received MV130 or placebo daily for 6 months. The primary endpoint was the number of WA within 1 year after the first dose comparing MV130 and placebo. There was a significant lower number of WA in MV130 versus the placebo group, 3.0 (interquartile range [IQR], 2.0–4.0) versus 5.0 (IQR, 3.0–7.0) (P < 0.001). Mucosal bacterial immunotherapy with MV130 shows safety and clinical efficacy against recurrent WA in children.
Like
Save
Share